Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19

Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.


There are currently no licensed vaccines against COVID-19, and the pandemic continues to spread in the U.S.  and around the world. CodaVax-COVID is a single-dose, intranasal, live-attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.

Safe and effective live-attenuated vaccines, presenting all target antigens

Target customized oncolytics to treat primary tumors and shrink off-site metastases


RSV hospitalizations among adults 65+ no vaccine

48.8 million

Flu cases in 2017-18, current vaccines <37% effective

1 in 8

US women (about 12%) will develop invasive breast cancer during lifetime.

Our breakthrough approach to live-attenuated virus design

1. Recode

2. Synthesize

3. Transfect

4. Recover

  • September 22, 2020

    Serum Institute of India Initiates Manufacturing of Codagenix’s Intranasal Live-Attenuated COVID-19 Vaccine Candidate

  • September 16, 2020

    Synthetic biologists have created a slow-growing version of the coronavirus to give as a vaccine